Sygnature Discovery offers a fully validated panel of electrophysiology assays spanning the KV1.x subfamily. Using automated electrophysiology platforms, each isoform was profiled to define its unique activation and inactivation kinetics, alongside pharmacological assessment using both broad-spectrum and subtype-selective inhibitors. The Kv1.x panel enables detailed analysis of potency, selectivity and mechanism of action, providing a robust platform for compound screening and mechanistic studies.
Introduction
Kv1 channels play essential roles in regulating neuronal excitability, immune cell function ad cardiac repolarisation. Kv1.3, in particular, has emerged as a target of interest in oncology, autoimmune and metabolic diseases, while other Kv1.x family members have been implicated in neurological and cardiovascular disorders. These findings highlight the value of isoform-resolved assays in supporting ion channel drug discovery across diverse therapeutic areas.
